From Blekinge Hospital, Karlskrona, Sweden Inclusion: age-related cataract Group 1: , mean age 72.5, 54.0% women, median VA 0.6/0.6 (right/left eye) prior to surgery Group 2: , mean age 72.5, 54.3% women, median VA 0.6/0.6 (right/left eye) prior to surgery Excluded after randomization: 6% in Group 1 and 10.9% in Group 2 No lost to follow-up: not reported
Group 1: ISBCS Group 2: sequential bilateral cataract surgery delayed by 2 months All had phacoemulsification
VA was 0.8 or better in 91.5% of patients in Group 1 and 91.3% of patients in Group 2. Two months after surgery total disability score (Catquest score): 7.0 in Group 1 and 7.0 in Group 2.
The study was supported by the County Council of Blekinge. No conflict of interests is noted.
From Helsinki University Eye Hospital, Helsinki, Finland Inclusion: age-related Group 1: mean (SD) age 75.3 (7.9), 73.6% women, preop CDVA (median) 20/60 Group 2: mean (SD) age 75.0 (8.1), 74.3% women, preop CDVA (median) 20/60 Excluded after randomization: 4% in Group 1 and 2.7% in Group 2 No lost to follow-up: 3.2% in total
Group 1: ISBCS Group 2: delayed sequential bilateral cataract surgery All had phacoemulsification
Postop VF-7: 24.3 (21.0) in Group 1 and 23.8 (19.2) in Group 2. Any complication (intraoperative up to 1 month postop): 106/493 in Group 1 and 124/506 in Group 2. Serious complications: 9/493 in Group 1 and 9/506 in Group 2. CDVA: 20/25 or better in 376/493 in Group 1 and 336/506 in Group 2.
The study was supported by private and public research grants. No conflict of interests was reported.
From several clinics on the Canary Islands, Spain Inclusion: age-related cataract Group 1: mean (SD) age 72.9 (8.2), 61.2% women, preop CDVA (median) 20/100 Group 2: mean (SD) age 71.7 (7.9), 60.5% women, preop CDVA (median) 20/100 Excluded after randomization: 5.0% in Group 1 and 3.7% in Group 2 No lost to follow-up: 0 patients
Group 1: ISBCS Group 2: delayed sequential bilateral cataract surgery All had phacoemulsification
Postop VA was reported as median. Any complication (intraoperative and postop + dry eyes): 39/834 in Group 1 and 59/780 in Group 2. Serious complications: 10/834 in Group 1 versus 3/780 in Group 2. VF-14: 93.3 (12.8) in Group 1 and 95.8 (8.5) in Group 2 one month after surgery on the last eye.
The study was supported by public research grants.
